Mirati Therapeutics, Inc. (NASDAQ:MRTX)’s share price traded down 9.2% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $17.10 and last traded at $17.25. 914,000 shares changed hands during mid-day trading, an increase of 65% from the average session volume of 553,326 shares. The stock had previously closed at $19.00.

Specifically, SVP Jamie Christensen sold 10,275 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $18.00, for a total transaction of $184,950.00. Following the completion of the sale, the senior vice president now directly owns 12,670 shares of the company’s stock, valued at approximately $228,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 22,544 shares of company stock valued at $355,176 over the last ninety days. Company insiders own 5.10% of the company’s stock.

A number of research analysts have recently commented on MRTX shares. Zacks Investment Research lowered Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. HC Wainwright reissued a “buy” rating on shares of Mirati Therapeutics in a report on Tuesday, November 7th. ValuEngine raised Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 15th. Oppenheimer Holdings, Inc. started coverage on Mirati Therapeutics in a report on Monday, September 18th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Leerink Swann raised Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price objective on the stock in a report on Tuesday, November 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $13.71.

Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.16. analysts expect that Mirati Therapeutics, Inc. will post -2.78 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at approximately $668,000. OxFORD Asset Management LLP acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at approximately $365,000. Dimensional Fund Advisors LP grew its holdings in Mirati Therapeutics by 68.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock valued at $3,939,000 after buying an additional 137,104 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Mirati Therapeutics in the 3rd quarter valued at approximately $268,000. Finally, Sabby Management LLC grew its holdings in Mirati Therapeutics by 2.1% in the 2nd quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock valued at $921,000 after buying an additional 5,365 shares during the last quarter. 59.80% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/21/mirati-therapeutics-inc-mrtx-stock-price-down-9-2-on-insider-selling.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.